DUBLIN--(BUSINESS WIRE)--The "COPD: Disease Inights and Market Forecasts to 2024" report has been added to ResearchAndMarkets.com's offering.
Disease Indication Overview:
The section highlights the basic definition, causes and symptoms of disease and details the types of COPD disease. Further details on the profile of COPD patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report.
Epidemiology Forecasts to 2024:
This section of the report provides the overview of COPD diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2015-2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.
Drugs Overview and Attribute Analysis:
This part of the report highlights the importance of factors influencing the physician prescription decisions in COPD disease including efficacy factors, Tolerability factors, Monitoring requirements and pricing factors. The report further details the drugs prescribed or expected to be prescribed in COPD disease by the physicians in terms of details about the formulation, molecule, mode of administration and mechanism of action of the drugs, their patent and trial details and the expected impact of drug in the COPD market.
Drugs and Market Forecast to 2024:
The forecasts are developed based on the detailed drug attribute analysis, conducted by Pharmascroll, as shared in the previous section. It is important to note that the Forecasts conducted by Pharmascroll are not based on simple projections, and are developed meticulously based on a complex forecasting model, owned by Pharmascroll, using multiple assumptions related to launch dates of the products in the market, price of the products, adherence and compliance rates of the products, dosages of the products etc.
- Boehringer Ingelheim
- Forest Laboratories
- Kyorin Holdings
- Daewoong Pharmaceutical
- Sumitomo Dainippon Pharma
- Meiji Holdings
- Pierre Fabre
- Laboratorios Farmacuticos ROVI
- Grupo Ferrer
- Mitsubishi Tanabe Pharma
- Endo International
- Aspen Pharmacare
- Faes Farma
- Dong-A ST
Key Topics Covered:
1 Table of Contents
2 Executive Summary
3 Disease Overview
4 Disease Epidemiology
5 Physian's Insights
6 Competitive Assessment and Attribute Analysis - Key Therapies
7 Pipeline Assessment
8 Market Outlook
9 Sales and Patient Forecast for Key Drugs
For more information about this report visit https://www.researchandmarkets.com/research/rpb7pg/copd_disease?w=4